J Korean Diabetes > Volume 14(3); 2013 > Article
The Journal of Korean Diabetes 2013;14(3):125-127.
DOI: https://doi.org/10.4093/jkd.2013.14.3.125    Published online September 30, 2013.
글루카곤양펩티드-1 (GLP-1) 유사체의 임상효과
전현지, 권혁상
Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues.
Hyun Ji Chun, Hyuk Sang Kwon
Department of Internal Medicine, Division of Endocrinology and Metabolism, The Catholic University of Korea, Seoul, Korea. drkwon@catholic.ac.kr
Recently, incretin hormone-based therapies, including glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become the main therapeutic tools in the hyperglycemia management in patients with type 2 diabetes mellitus. These therapeutic agents could fill an important gap in glycemic control for patients with type 2 diabetes because the incretin response is blunted in type 2 diabetes mellitus. GLP-1 analogues can be classified as exendin-4 backbone (Exenatide, Exenatide LAR and Lixisenatide) and human GLP-1 backbone (Liraglutide, Taspoglutide and Albiglutide). Among these, Exenatide, Exenatide LAR and Liraglutide are currently available. This review will focus on the clinical efficacies of GLP-1 analogues in glycemic control for patients with diabetes.
Key Words: Type 2 diabetes mellitus, GLP-1 analogues, Incretins

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2024 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer